Co-Diagnostics, Inc. Common Stock
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provide… Read more
Co-Diagnostics, Inc. Common Stock (CODX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.148x
Based on the latest financial reports, Co-Diagnostics, Inc. Common Stock (CODX) has a cash flow conversion efficiency ratio of -0.148x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.90 Million) by net assets ($39.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Co-Diagnostics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Co-Diagnostics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Co-Diagnostics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Co-Diagnostics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
California First National Bancorp
OTCQX:CFNB
|
0.003x |
|
Grey Cloak Tech Inc
OTCQB:HYEX
|
-0.012x |
|
DUG Foodtech AB (publ)
ST:VUXEN
|
0.090x |
|
DRC Systems India Limited
NSE:DRCSYSTEMS
|
0.019x |
|
Ravelin Properties REIT
TO:RPR-UN
|
0.020x |
|
Glacier Media Inc
PINK:GLMFF
|
-0.056x |
|
MILIBOO. S.A. EO -10
F:7X2
|
N/A |
|
Toppoint Holdings Inc.
NYSE MKT:TOPP
|
-0.049x |
Annual Cash Flow Conversion Efficiency for Co-Diagnostics, Inc. Common Stock (2014–2024)
The table below shows the annual cash flow conversion efficiency of Co-Diagnostics, Inc. Common Stock from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $54.31 Million | $-29.16 Million | -0.537x | -109.10% |
| 2023-12-31 | $86.01 Million | $-22.08 Million | -0.257x | -547.58% |
| 2022-12-31 | $114.52 Million | $6.57 Million | 0.057x | -81.22% |
| 2021-12-31 | $134.48 Million | $41.08 Million | 0.305x | -27.66% |
| 2020-12-31 | $66.70 Million | $28.17 Million | 0.422x | +113.28% |
| 2019-12-31 | $1.74 Million | $-5.53 Million | -3.180x | -182.53% |
| 2018-12-31 | $-1.06 Million | $-4.08 Million | 3.853x | +562.03% |
| 2017-12-31 | $3.85 Million | $-3.21 Million | -0.834x | -290.32% |
| 2016-12-31 | $-2.99 Million | $-1.31 Million | 0.438x | -67.15% |
| 2015-12-31 | $-1.15 Million | $-1.53 Million | 1.334x | +119.98% |
| 2014-12-31 | $138.63K | $-925.23K | -6.674x | -- |